FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健培苗苗(保健)有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02161 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | 本月 ...

Group 1 - The stock of Jianbei Miaomiao (02161.HK) increased by over 5%, specifically by 5.19%, reaching a price of 3.04 HKD [2] - The trading volume amounted to 1.5588 million HKD [2]

Group 1 - The company "健倍苗苗" announced a dividend of HKD 0.0975 per share, with an ex-dividend date of November 28, 2025, and a payment date of December 17, 2025 [1] - The 中证港股通央企红利指数 (CSI) consists of 50 high-dividend stocks from central enterprises, with a one-year dividend yield of 5.59% as of November 17, which is higher than the 10-year government bond yield of 3.77% [1] - The 恒生中国内地企业高股息率指数 (HSMCHYI) includes high-dividend stocks from mainland companies listed in Hong Kong, with a one-year dividend yield of 5.25% as of November 17, surpassing the 10-year government bond yield of 3.43% [1] Group 2 - The 港股央企红利ETF (513910) is the largest investment vehicle tracking the CSI index [1] - The 恒生红利ETF (159726) is the only ETF tracking the HSMCHYI index [1]

Core Viewpoint - The company Jianbei Miao Miao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly in the branded pharmaceuticals segment with He Ji Gong and the traditional Chinese medicine segment with Bao Ji Wan [1] - The company's focus on brand management and effective market promotion execution contributed to the positive sales performance [1] - The traditional Chinese medicine formula granules business also showed stable performance, providing continuous contributions to the health business group [1]

Core Viewpoint - The company Jianbei Miaomiao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly the branded pharmaceutical segment's He Jigong and the traditional Chinese medicine segment's Baoji Wan [1] - The company attributed its success to focused brand management and effective market promotion execution [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]

Core Viewpoint - The company, Jianbei Miaomiao (02161), announced a mid-term dividend of HKD 0.0975 per share, to be distributed on December 17, 2025 [1] Company Summary - Jianbei Miaomiao will distribute a mid-term dividend of HKD 0.0975 per share [1]

Core Viewpoint - The company reported a revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - The earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Revenue Performance - The revenue growth was primarily driven by strong sales performance of core brands, particularly the branded pharmaceutical segment's He Ji Gong and the traditional Chinese medicine segment's Bao Ji Wan [1] - Focused brand management and effective market promotion execution contributed to the sales performance [1] Business Segments - The Chinese medicine formula granules business showed stable performance, continuously contributing to the brand health business group [1]

Core Viewpoint - The company,健倍苗苗(02161), announced a mid-term dividend of HKD 0.0975 per share to be distributed on December 17, 2025 [1] Group 1 - The mid-term dividend reflects the company's ongoing commitment to returning value to shareholders [1]

Core Viewpoint - The company reported a significant increase in revenue and profit for the six months ending September 30, 2025, indicating strong financial performance compared to the previous year [1] Financial Performance - Revenue for the six months was approximately HKD 430 million, an increase of about 7.7% from approximately HKD 400 million in the same period of 2024 [1] - Operating profit for the same period was around HKD 150 million, reflecting a growth of approximately 23.8% from about HKD 122 million in 2024 [1] - Profit attributable to equity holders was approximately HKD 115 million, which is a 20.0% increase from around HKD 95.9 million in 2024 [1] Dividend Declaration - The board declared an interim dividend of HKD 0.0975 per ordinary share, totaling approximately HKD 8.01 million, which is an increase of about 77.3% compared to HKD 0.055 per ordinary share (totaling approximately HKD 45.2 million) in 2024 [1]

Core Viewpoint - The company reported a strong performance in its interim results for the six months ending September 30, 2025, with significant growth in revenue and profit driven by robust sales of its core brands [1] Financial Performance - Revenue reached approximately HKD 430 million, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Business Segments - The growth in performance was primarily attributed to strong sales in the branded pharmaceutical segment, particularly the He Ji Gong brand, and the traditional Chinese medicine segment, especially the Bao Ji Wan product [1] - The company emphasized effective brand management and successful market promotion as key factors in driving sales [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]